 |
Functional Genomics and Chromatin: Why understanding gene expression regulation is essential to revolutionize cancer therapy? |
|
|
|
207-213 |
|
|
Novel Techniques in Radiation Therapy |
|
|
|
214-216 |
|
|
Minimally invasive total mesorectal excision for extraperitoneal rectal cancer: Why patients should seek specialized hospitals and surgeons? |
|
|
|
217-219 |
|
|
KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision? |
|
|
|
220-222 |
|
|
Field-in-Field Technique as a Treatment of Choice in Tangential Whole Breast Irradiation |
|
|
|
223-225 |
|
|
Assessing resistance to neoadjuvant treatment for breast cancer |
|
|
|
226-228 |
|
|
Cytoreductive Surgery for Ovarian Cancer: Is Splenectomy indicated? |
|
|
|
229-231 |
|
|
Peritoneal recurrence: The challenge in gastric cancer treatment and efforts to prevent |
|
|
|
232-234 |
|
|
Total gastrectomy: Preventing hereditary diffuse gastric cancer |
|
|
|
235-237 |
|
|
Breast cancer risk-reducing surgery and BRCA testing |
|
|
|
238-240 |
|
|
Sigmoid or rectal cancer: do patients benefit from high ligation of inferior mesenteric artery? |
|
|
|
241-243 |
|
|
HER2 status-based selection of gastric cancer patients for trastuzumab treatment. |
|
|
|
244-246 |
|
|
How to prevent or treat hereditary diffuse gastric cancer? |
|
|
|
247-249 |
|
|
Asymmetric open field-in-field can replace wedged fields in tangential whole breast irradiation |
|
|
|
250-255 |
|
|
Translational advances and challenges for pharmacogenomics-based prescription of drugs |
|
|
|
256-261 |
|
